News

  • 23 May 2019

    Janssen’s Invokana secures FDA priority review status

    Janssen Pharmaceutical has received priority review from the US Food and Drug Administration (FDA) for its Invokana (canagliflozin) medicine in type 2 diabetes (T2D) patients with chronic kidney disease (CKD).

Close
Close
Close

Go Top